Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.

Ludger Klimek Marek JutelJean BousquetIoana Agache Mübeccel Akdis Valerie Hox Philippe Gevaert Peter-Valentin Tomazic Carmen Rondón Cemal Cingi Sanna Katriina Toppila-SalmiAspasia KaraveliaBanu Bozkurt Ulrike Förster-RuhrmannSven BeckerAdam M Chaker Barbara Wollenberg Ralph Mosges Tilman Huppertz Jan Hagemann Claus Bachert Wytske Johanna Fokkens

Published in: Allergy (2021)

Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.

Keyphrases

end stage renal disease
minimally invasive
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
risk factors
combination therapy
coronavirus disease
patient reported